Can Testing Drugs in Five Species Help Us Find Treatments for Healthy Aging?

A new study describes a large cross-species testing system—using species from yeast to mice—to identify promising lifespan-extending drug candidates more efficiently.

(The study tested for lifespan extension in five model organisms | NAD.com)

A new platform tests aging intervention drugs in five animal model species—yeast, worms, flies, fish, and mice.

Aging &amp; Longevity

Model: Male C57BL/6J (B6) mice (15 months old at the start of treatment)
Dosage: Approximately 5 mg/kg/day of S-1-propenyl-L-cysteine (S1PC) was administered orally for 8 months, from 15 to 23 months of age. S1PC was given in chow containing 0.0025% S1PC, with a second experiment using drinking water to confirm the findings.

Researchers found that a compound found in garlic supports healthier muscle aging by boosting cellular defenses linked to longevity and maintaining physical performance.

Skin &amp; Muscle

Model: SAMP8 mice (5 months old) and C57BL/6 mice (16 months old)
Dosage: 1.5 mg/kg of urolithin A was administered by intraperitoneal injection three times per week (Monday, Wednesday, and Friday) for 8 weeks.

Study shows that urolithin A preserves memory and cognitive function during aging when treatment begins before age-related decline, but does not reverse cognitive impairment once it is established.

Brain &amp; Neurons

Model: Skin, arterial, and lens tissue from donors between the ages of 20 and 25 and also 75 
Dosage: 5 µM solution of CMLase, incubated overnight

Bioengineered Enzyme Shows Ability to Reverse Molecular Aging in Human Tissue

An engineered enzyme reverses age-related protein damage that researchers have long thought irreversible in human eye, skin, and artery tissues.

(A bioengineered enzyme [purple structure] cleaves a prevalent type of AGE [brown glob] on protein residues that are part of protein filaments [dull green chains] | The Scientist)

A bioengineered enzyme reverses age-related protein damage, long thought of as irreversible damage, in human lens, skin, and artery tissues.

Basic Research

Model: Older adults (60–85 years old) with mild cognitive impairment (MCI) enrolled in a randomized, double-blind, placebo-controlled clinical trial.
Dosage: Participants received one gastro-resistant capsule daily for 180 days, containing either 250 mg of Kluyveromyces fragilis yeast extract, 350 mg of Saccharomyces cerevisiae yeast extract, or a placebo.

Yeast Supplement Improves Cognitive Function in Older Adults with Mild Cognitive Impairment

Daily supplementation with nucleotide-rich yeast extracts improves cognitive performance and mental well-being in older adults with mild cognitive impairment, researchers find. 

Search Result: quality of life

Can Testing Drugs in Five Species Help Us Find Treatments for Healthy Aging?

Garlic-Derived Compound Activates a Natural Anti-Aging Pathway That Preserves Muscle Function

Urolithin A Preserves Memory During Aging When Treatment Begins Early, Study Shows

New Research: Bioengineered Enzyme Shows Ability to Reverse Molecular Aging in Human Tissue

Yeast Supplement Improves Cognitive Function in Older Adults with Mild Cognitive Impairment